Using flow cytometry we detected a 2.7-fold upregulation of ICAM-1 in MB-PDT-treated lung cancer cells compared to untreated cells 24 h post-treatment and 6.4-fold upregulation in MB-PDT-treated cells 48 h post-treatment. This evidence concerns the gene ICAM1 and lung carcinoma.